ARVINAS, INC. Marketable Securities (Current)
ARVINAS, INC. (ARVN) had Marketable Securities (Current) of $473.60 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-04
- 2026-06-30: Marketable Securities, Current $473.60M.
- 2026-03-31: Marketable Securities, Current $527.60M.
- 2025-12-31: Marketable Securities, Current $542.50M.
- 2025-09-30: Marketable Securities, Current $686.10M.
| Period end | Marketable Securities, Current | Marketable Securities, Current as first filed |
|---|---|---|
| 2026-06-30 | $473.60M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $527.60M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $542.50M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $686.10M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $746.30M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $873.30M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $938.90M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $1.04B 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $1.07B 10-Q · filed 2024-07-30 | |
| 2024-03-31 | $1.08B 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $949.30M 10-K · filed 2025-02-11 | |
| 2023-09-30 | $884.80M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $948.20M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $993.30M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $1.12B 10-K · filed 2024-02-27 | |
| 2022-09-30 | $1.14B 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $1.25B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $1.37B 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $1.39B 10-K · filed 2023-02-23 | |
| 2021-09-30 | $1.29B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $551.85M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $305.20M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $100.20M 10-K · filed 2022-02-28 | $100.16M 10-K · filed 2021-03-01 |
| 2020-09-30 | $159.57M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $221.10M 10-Q · filed 2020-08-04 | |
| 2020-03-31 | $226.73M 10-Q · filed 2020-04-28 | |
| 2019-12-31 | $271.66M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $178.38M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $147.83M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | $146.18M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $184.64M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $83.60M 10-Q · filed 2018-11-14 | |
| 2017-12-31 | $8.26M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |